Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging H5N1 AS03-adjuvanted vaccine priming study in children 6 to <36 months
2015-003458-42Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted in Influenza A infection (6 arms), sponsored by GSK. Primary endpoint: Immunogenicity-fever index based on homologous HI and MN antibodies. Started Feb 2016; status: completed.
02
Drugs
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2015-003458-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003458-42.